Ventures Vi Lprmv Vi, L.L.C... Net Worth

The estimated Net Worth of Ventures Vi Lprmv Vi, L.L.C... is at least $1.03 million dollars as of 31 March 2017. Ventures C owns over 500,000 units of Cara Therapeutics Inc stock worth over $1,034,737 and over the last 8 years Ventures sold CARA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures C CARA stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Cara Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Ventures bought 500,000 units of CARA stock worth $9,095,000 on 31 March 2017.

The largest trade Ventures's ever made was buying 500,000 units of Cara Therapeutics Inc stock on 31 March 2017 worth over $9,095,000. On average, Ventures trades about 500,000 units every 0 days since 2017. As of 31 March 2017 Ventures still owns at least 3,568,057 units of Cara Therapeutics Inc stock.

You can see the complete history of Ventures C stock trades at the bottom of the page.

Insiders trading at Cara Therapeutics Inc

Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum et Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.

What does Cara Therapeutics Inc do?

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Complete history of Ventures C stock trades at Cara Therapeutics Inc

Cara Therapeutics Inc executives and stock owners

Cara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joana Goncalves,
  Chief Medical Officer
• Derek Chalmers,
  President, Chief Executive Officer, Director
• Frederique Menzaghi,
  Senior Vice President, Research and Development, Chief Scientific Officer
• Scott Terrillion,
  Chief Compliance Officer, General Counsel, Secretary
• Dr. Derek T. Chalmers D.Sc., Ph.D.,
  Co-Founder & Sr. Advisor
• Dr. Frédérique Menzaghi,
  Chief Scientific Officer and Sr. VP of R&D
• Dr. Joana Goncalves,
  Chief Medical Officer
• Scott M. Terrillion,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Richard Makara,
  VP, Head of Accounting, Controller & Principal Accounting Officer
• Martin Vogelbaum,
  Lead Independent Director
• Harrison Bains,
  Independent Director
• Christopher Posner,
  Independent Director
• Jeffrey Ives,
  Independent Director
• Thomas Charles Reilly,
  Chief Financial Officer
• Christopher A. Posner,
  Pres, CEO & Director
• Susan Shiff,
  Director
• Richard Makara,
  Vice President, Head of Accounting & Controller
• Thomas Reilly,
  Chief Financial Officer
• Eric Vandal,
  Sr. VP of Commercial
• Dr. Michael E. Lewis Ph.D.,
  Co-Founder & Chief Scientific Advisor
• Ventures Vi Lprmv Vi, L.L.C...,
  
• Josef Schoell,
  Chief Financial Officer
• Dean Slagel,
  Director
• Ventures Vi Lprmv Vi, L.L.C...,
  
• Michael E Lewis,
  Chief Scientific Advisor
• Joseph William Stauffer,
  Chief Medical Officer
• Robert Medve,
  Chief Medical Officer
• Ventures Vi Lp Rho Capital ...,
  
• Charles Ph.D. Moller,
  Director
• Biopharma Partners Iii Lpal...,
  
• Edward Hurwitz,
  Director
• Ryan D Maynard,
  CHIEF FINANCIAL OFFICER
• Moltke Lisa Von,
  
• Helen M Boudreau,